



## **Dicot applies for patent covering new manufacturing technology**

**Press release: Uppsala, Sweden, January 11, 2024. The pharmaceutical company Dicot has applied for a patent covering a novel technology to manufacture the starting material for its potency drug candidate. It concerns a custom-designed approach in cell cultivation developed in partnership with Uppsala University.**

In 2022, Dicot started a research project with Uppsala University and W. Szafer Institute of Botany to investigate whether the starting material for the drug candidate LIB-01 could be produced by using plant cells grown in cultures; an established technology for large-scale commercial production of many medicinal substances originally derived from nature.

According to the company, the project - in which a custom-designed method is used to produce cells and grow them - has been successful in demonstrating at a laboratory scale that the technology works. Therefore, the project will now progress to larger-scale testing. At the same time, a patent application is submitted to the Swedish Patent and Registration Office to protect this way of producing the starting material. The action will be followed by further patent applications on several other relevant markets.

"We continue to consistently advance our positions to broaden and strengthen the patent protection in accordance with our IP strategy. Our cell culture method is at the forefront and after a successful project with Uppsala University we now have enough data to be able to apply for a patent. The protection is important as the technology is highly promising for future commercial production of our starting material," says Elin Trampe, CEO at Dicot.

### **For further information, please contact:**

Elin Trampe, CEO

Phone: +46 72 502 10 10

E-mail: [elin.trampe@dicot.se](mailto:elin.trampe@dicot.se)

### **About Dicot AB**

Dicot is developing the drug candidate LIB-01, which will be a potency agent to better treat erectile dysfunction and premature ejaculation. The ambition is to create a drug with significantly longer effect and far fewer side effects, compared to current available drugs. Today, over 500 million men suffer from these sexual dysfunctions and the market is valued at USD 8 billion. Dicot's strategy is to develop LIB-01 under own auspices until phase 2a studies and thereafter in partnership with larger, established pharmaceutical companies, finance and develop LIB-01 further to a registered pharmaceutical on the world market.

Dicot is listed on Spotlight Stock Market and has approximately 5,000 shareholders. For more information, please visit [www.dicot.se](http://www.dicot.se).